Abstract
Thyroid eye disease (TED) is an autoimmune condition usually associated with thyroid dysfunction and characterised by inflammatory and fibrotic changes in the periocular tissues. It is most commonly associated with hyperthyroidism, but patients with TED may also be hypothyroid or euthyroid, and it does not always present at the same time as the thyroid dysfunction. Patients may present with inflamed eyes, ocular surface discomfort, double vision, and proptosis and may even progress to optic nerve compression and visual loss.
Risk factors include smoking and radioiodine treatment. Early recognition is important since treatment in the active phase with steroids, immunomodulatory agents, and sometimes radiotherapy can prevent persistent disability and disfigurement. Once the disease is inactive, treatment is focused more on surgical rehabilitation, with orbital decompression, strabismus surgery, and lid surgery. Urgent orbital decompression may be needed if the optic nerve is compressed. People with TED may have significant psychological distress related to hormonal changes, vision problems, changing appearance, and medication side effects, and the psychological care of these patients is often neglected. Future developments may offer the possibility of earlier diagnosis, biologic treatments tailored to the disease to stop its activity, and effective less invasive surgical rehabilitation.
It is imperative that clinical practitioners are familiar with the clinical features of Graves’ ophthalmopathy. Furthermore, the thyroid endocrine nurse must be equipped with the relevant knowledge and understanding of eye anatomy and how thyroid eye disease (TED) presents. In this way, any eye signs and symptoms can be identified early, and managed more effectively, potentially reversing GO if referred promptly to an ‘endocrine’ ophthalmologist who specialises in thyroid eye disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- CD20 marker:
-
CD20, a transmembrane protein expressed on the surface of pre-B and mature B lymphocytes
- CN:
-
Cranial nerve
- CT:
-
Computerised tomography
- EUGOGO:
-
European Group on Graves’ Orbitopathy
- FT3:
-
Free total triiodothyronine
- fT4:
-
Free thyroid hormone or thyroxine
- GP:
-
General practitioner
- IGF-IR inhibitor:
-
Insulin-like growth factor-I receptor (inhibits targets of signaling pathways)
- MDT:
-
Multidisciplinary team
- MRI:
-
Magnetic resonance imaging
- NOSPECS:
-
Mnemonic often is used as a scoring system for severity of eye change
- RAI:
-
Radioactive iodine
- STIR:
-
Short Tau Inversion Recovery (used with MRI)
- TED:
-
Thyroid eye disease
- TPO antibodies:
-
Thyroid peroxidase antibodies
- TSH receptor:
-
Thyroid-stimulating hormone receptor
- TSH:
-
Thyroid stimulation hormone
- UK:
-
United Kingdom
- USA:
-
United States of America
- VISA:
-
vision, Inflammation, strabismus, and appearance
References
British Thyroid Association (BTA). UK guidelines for the use of thyroid function tests: thyrotoxicosis (online). BTA. 2006. http://www.british-thyroid-association.org/sandbox/bta2016/uk_guidelines_for_the_use_of_thyroid_function_tests.pdf. Accessed 22 Apr 2018.
British Thyroid Foundation. Thyroid eye disease (online). BTF. 2015. http://www.btf-thyroid.org/information/leaflets/36-thyroid-eye-disease-guide. Accessed 22 Apr 2018.
Hogan-Quigley B, Palm ML, Bickley L. Bates’ Nursing guide to Physical Examination and History taking. London: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
Khong JJ, McNab AA, Ebeling PR, et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100:142–50.
National Institute for Health and Care Excellence (NICE). Hyperthyroidism (online). NICE. 2016. https://cks.nice.org.uk/hyperthyroidism#!management. Accessed 22 Apr 2018.
Perros P, Dayan CM, Dickinson AJ, et al. Management of patients with Graves’ orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clin Med. 2015;15(2):173–8. https://doi.org/10.7861/clinmedicine.15-2-173.
Perros P, Hegedus L, Bartelena L, Weirsinga WM, et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12:72. https://doi.org/10.1186/s13023-017-0625-1.
Thyroid Eye Disease Charitable Trust. An introduction to thyroid eye disease (online). TEDct. 2017. http://tedct.org.uk/thyroid-eye-disease. Accessed 22 Aug 2017.
Verity D, Rose GE. Acute thyroid eye disease (TED): principles of medical and surgical management. Eye. 2013;27:308–19.
Weiler DL. Thyroid eye disease: a review. Clin Exp Optom. 2017;100:20–5. https://doi.org/10.1111/cxo.12472.
Wiersinga WM. Graves’ ophthalmopathy and dermopathy-3.3.10. In: JAH W, Stewart PM, Amiel SA, Davies MJ, editors. Oxford textbook of endocrinology and diabetes. Oxford: Oxford University Press; 2011.
Key Reading
Verity DH, Rose GE. Acute thyroid eye disease (TED): Principles of medical and surgical management. Eye. 2013;27:308–19.
Bartelena L, Baldeschi L, et al. on behalf of EUGOGO: The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5:9–26.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ford, R., Fazal-Sanderson, V. (2019). Thyroid Eye Disease. In: Llahana, S., Follin, C., Yedinak, C., Grossman, A. (eds) Advanced Practice in Endocrinology Nursing. Springer, Cham. https://doi.org/10.1007/978-3-319-99817-6_31
Download citation
DOI: https://doi.org/10.1007/978-3-319-99817-6_31
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99815-2
Online ISBN: 978-3-319-99817-6
eBook Packages: MedicineMedicine (R0)